Source-checked guide

GLP-1 Match: What It Does and What to Check Before Care

By the Clinic Scout Editorial Team · Updated October 9, 2026

Sources current as of 2026-10-09 · Prices checked 2026-10-09 – 2026-10-09 · Prices and terms can change.

GLP-1 Match at GLP1Match.com helps people discover telehealth providers; it is not a clinic and does not provide medical treatment. Treat a match as a shortlist, not medical clearance. Check the provider’s own terms, complete costs, medication and clinician review. The site discloses that affiliate relationships may influence provider presentation. [S2] [S3]

Which GLP-1 Match website are you looking for?

The semaglutide and tirzepatide medications discussed here require a prescription from an appropriately licensed clinician. A directory match is neither a prescription nor clinical approval and cannot authorize access to prescription medication. FDA advises obtaining a prescription from a doctor and flags services that supply these medicines without screening and a prescription by a licensed doctor. [S14]

The spelling matters. The homepage at GLP1Match.com offers state and medication filters and a “Verified Providers Only” control. MatchGLP1.com is a different domain whose homepage offers a quiz, comparison pages and rankings. These observations identify the pages we checked; they do not establish that the businesses are affiliated, that their checks are equivalent or that either selects appropriate treatment. [S1] [S5]

If you came here looking for the GLP-1 Match site itself, the first-party GLP1Match.com homepage and its terms are the direct references. These are informational links, not an endorsement or a provider application. We have not completed either site’s quiz, submitted health information, tested a referral or purchased care.

For a broader explanation of online care, use our online GLP-1 prescription guide. This page focuses on what a directory match does and does not establish, rather than duplicating a provider ranking or helping you choose a medication yourself.

Which GLP-1 Match website are you looking for?
Website or role	What the checked page establishes
GLP1Match.com	Homepage offers provider discovery; terms say it is an aggregator and not a healthcare provider. [S1] [S2]
MatchGLP1.com	Separate domain advertises a matching quiz, provider comparison and rankings. [S5]
A provider selected through GLP1Match.com	Its own terms and privacy practices apply independently of the directory, according to the directory’s terms. [S2]

What GLP1Match.com says it does

The directory’s terms say it helps users locate telehealth providers who may prescribe and deliver GLP-1 medications. They describe searching and comparing by criteria such as location, specialty and price. They also say the platform does not provide medical services, diagnosis or treatment, and does not recommend or endorse a specific medication or healthcare provider. [S2]

That is a narrower role than an appointment with a licensed professional. Our editorial approach is to use a directory result as an organizational aid: collect a provider’s name, save the source of the listing, and identify the questions still unanswered. Leave the clinical decision with a qualified healthcare professional rather than translating a website filter into a treatment decision.

The terms explicitly do not warrant that provider qualifications, pricing, availability or insurance coverage are complete, accurate, reliable or error-free. A useful listing therefore still needs a current check with the provider or plan. This is the site’s stated limitation, not evidence that any particular listing is wrong. [S2]

Start with a distinction in your notes: “reported by the directory” versus “confirmed directly for my situation.” For example, write the advertised service next to a blank space for the provider’s written response. Do not replace that blank with an assumption because a result appeared near the top of a list. An unresolved answer is unresolved, not a positive or a negative finding.

What does “Verified Providers Only” prove?

The GLP1Match.com homepage we checked includes the words “Verified Providers Only.” The captured homepage does not explain the verification criteria next to that control. We did not independently establish what was checked, by whom, when it was checked, or whether that check extends to the particular clinician and pharmacy involved in a future prescription. [S1]

Ask the directory what its verification covers before relying on the label. Useful questions include whether it checks a business identity, clinician licensing, dispensing-pharmacy licensing, pricing accuracy or some other attribute. Ask when the relevant record was last reviewed and how corrections are handled. These are our suggested questions, not findings about the directory’s internal process.

Avoid both extremes: a badge is not enough evidence to declare a provider safe for you, but a short homepage capture is not enough evidence to declare the provider unsafe. The absence of an explanation in our capture is a limitation of the evidence available for this guide. It is not proof that the directory has no verification procedure.

For the pharmacy portion of your checklist, see how to verify an online GLP-1 pharmacy. Keep the names of the directory, the clinical service and the dispensing pharmacy separate in your notes so that a question reaches the party responsible for answering it.

Affiliate disclosure: why the order of a list is not a clinical finding

GLP1Match.com’s disclosure says some links may be affiliate links and that it may receive a commission after a purchase or another qualifying action. It also states that affiliate relationships may influence which providers or products appear and where or how they are presented. The page separately describes potential sponsorships, paid insertions and advertisements. Its discount-code terms say using a code may give you a discount while GLP1Match.com may receive compensation, such as a commission or referral fee. [S3] [S13]

The same disclosure says paid advertisements do not imply endorsement or approval, and it tells users to consult a qualified healthcare professional before making medical decisions. We report those statements as the platform’s own disclosures; we have not audited its commercial relationships, payments or ranking algorithm. [S3]

Our recommendation is to ask how a particular result was selected. Distinguish an alphabetical directory, a response to your nonclinical filters, an editorial ranking and a sponsored placement. If the page does not explain the order, keep the reason unknown. Do not infer that the first result has superior clinical outcomes or that a discount code establishes a lower complete bill.

GLP Clinic Scout’s affiliate disclosure says we may earn a commission at no extra cost to you if you use a partner link. [S19] This guide contains no provider affiliate call to action. The practical standard is the same whichever comparison site you use: identify the source, distinguish commercial presentation from medical evidence, and check the terms before committing. Disclosure helps you interpret content; it is not a substitute for verification.

Compare complete costs, not a directory headline

Two pages in the exact-query search results illustrate the problem. GoodRx’s online weight-loss care page says “Medication cost not included” and “GoodRx is NOT insurance.” Weight Watchers’ MED+ offer similarly says GLP-1 medication costs are not included; its footnote describes different commitment lengths, continuing membership rates and automatic renewal. These are reported page terms, not quotes for your care or recommendations to use either service. [S6] [S7]

We deliberately do not compare those offers as if the first displayed number were a complete medication price. Instead, ask each shortlisted provider for a written breakdown for the same time period. Save a date with the response. A directory headline and a checkout summary answer different questions, and neither should be silently substituted for the other.

This table is an editorial request list, not a claim that every provider charges each item. If the service answers “included,” record exactly what is included and for how long. If it gives a range, preserve the range and its conditions instead of using the lowest endpoint as your expected total. Do not estimate an unknown medication bill as zero to make the comparison look complete.

Our guide to comparing online GLP-1 provider fees goes further into organizing those responses. For this directory search, the immediate goal is simpler: know which organization you would pay and what the payment would purchase before a match becomes a subscription.

Compare complete costs, not a directory headline
Cost question	What to request before paying
Clinical-service charge	Ask whether visits, messaging and follow-up are included, and which items are separate.
Medication charge	Request the exact product and presentation, quantity, billing period and pharmacy price.
Other costs	Ask about any required labs, supplies or shipping; leave unconfirmed items unknown.
Commitment and renewal	Ask about prepaid terms, the next renewal date and how cancellation works.
Coverage uncertainty	Ask for the plan’s decision and your patient responsibility, rather than treating assistance as approval.

Check the medication separately from the provider match

A product name needs its own evidence. For example, the current U.S. Zepbound prescribing-information highlights identify tirzepatide as a GIP and GLP-1 receptor agonist. They indicate use with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or overweight with at least one weight-related comorbid condition. They also include moderate-to-severe obstructive sleep apnea in adults with obesity. These are Zepbound-specific label statements, not a finding about a directory’s eligibility filters. [S8] (original PDF page 1)

The label also carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and whether Zepbound causes these tumors in humans is unknown. It lists contraindications including a personal or family history of medullary thyroid carcinoma or MEN 2, and known serious hypersensitivity to tirzepatide or its excipients. This is a selected safety summary, not a complete screening checklist. [S8] (original PDF page 1)

Page 1 additionally warns about severe gastrointestinal reactions, acute kidney injury due to volume depletion, gallbladder disease, pancreatitis and serious hypersensitivity reactions. It includes pregnancy precautions and notes potential effects on absorption of oral medications. A comparison filter cannot evaluate those issues; take the full product information and your medical history to a qualified clinician. [S8] (original PDF page 1)

We cite that label to show why product-specific clinician review belongs outside a directory match. We are not using Zepbound’s label as evidence for a compounded preparation, another brand or a particular provider’s service. Ask what exact product is proposed and request its relevant information. A shared ingredient name is not permission to substitute a different product’s label or a trial statistic for the proposed treatment.

Can research identify your personal GLP-1 match?

The original studies retained for this guide do not validate either directory’s matching process. One retrospective study used health-system records from Ohio and Florida to examine adults with overweight or obesity, without type 2 diabetes, who started injectable semaglutide or tirzepatide. It followed changes through 12 months by discontinuation status. Its authors reported lower average weight reduction than in the main phase 3 trials, likely related to more discontinuation and lower maintenance dosages. This is observational evidence, not a causal test of provider matching. [S10]

A second retrospective study from the same geographic health-system setting examined people who discontinued those medications after starting them for obesity or type 2 diabetes. During the year after discontinuation, restarting the original medication or receiving alternative treatment was common. Average weight change was relatively small, with considerable individual variability. Because later treatment was common, the findings should not be read as the effect of stopping medication without further care. [S11]

That second study matters as contrary evidence to a blanket claim that every person follows the same trajectory after stopping. It does not establish that stopping is risk-free or appropriate for you. The studies address different populations and follow-up questions; their averages do not settle an individual treatment plan. Our editorial takeaway is to ask the clinician how follow-up and continuity would be handled, not to predict your result from an average. [S10] [S11]

A third, nationwide multicenter observational study compared short-term adverse events, persistence and effectiveness among people with obesity receiving semaglutide or tirzepatide, with analyses through six months. It reported similar overall short-term tolerability and persistence alongside differences in some events and early weight reduction. Treatment was not randomly assigned, so the comparison is not proof that one drug, provider or directory is the best match for an individual. [S12]

We also inspected the SURMOUNT-5 trial protocol. Original PDF page 13 describes the weight-change endpoint at 72 weeks; page 14 describes a randomized, open-label, active-controlled comparison in adults with obesity or overweight without type 2 diabetes. Those pages describe study design, not outcome findings. We do not convert the protocol’s objective to demonstrate superiority into a demonstrated result. [S9] (original PDF pages 13–14)

Can research identify your personal GLP-1 match?
Evidence checked	Boundary on what it can tell you
Zepbound U.S. prescribing information	Product-specific approved-use and safety information; not directory approval. [S8]
Ohio/Florida observational cohorts	Routine-care associations and variation; no randomized test of matching sites. [S10] [S11]
Short-term multicenter observational comparison	Group-level observations through six months; not individual drug selection. [S12]
SURMOUNT-5 protocol pages	Planned study design and endpoint; these pages are not an outcomes report. [S9]

Privacy: check the directory and the care provider separately

GLP1Match.com’s privacy policy describes it as an aggregator, not a healthcare provider, and says it does not collect medical or health-related information. It states that it does not act as a HIPAA covered entity or business associate. These are policy statements, not an independent security or legal-compliance audit. Do not assume a directory account has the same protections or purpose as a clinical patient portal. [S4]

The policy describes collection of contact information when supplied, and automatic device and usage information including IP addresses, referring URLs, pages viewed and links clicked. It names cookies, pixels, Hotjar and Google Analytics. It also describes sharing with service vendors and says, currently, it does not share personal information such as email with telehealth providers. We have not tested whether its live tracking or data flows match those statements. [S4]

The directory’s terms say a selected provider’s privacy practices apply independently. Our recommendation is to read that provider’s notice before entering sensitive information. Ask which organization receives an intake, whether you are in a clinical portal and what happens to data if you decide not to proceed. Do not send medical history to a comparison publisher merely to obtain general reading material. [S2]

A practical way to use a match without overreading it

Use three columns in your own notes: the directory’s statement, the responsible party’s response, and the date of that response. Start with administrative questions: the provider’s legal name, service in your state, the clinician involved, the proposed product, the pharmacy, complete costs and cancellation terms. This is a suggested documentation method, not a score that certifies a provider or calculates treatment eligibility.

Before a payment, ask what happens if a clinician does not prescribe, if the proposed product is unavailable, or if your plan declines coverage. Request the relevant terms rather than assuming the outcome. Keep any unresolved issue visible. If the next step requests health history, confirm the organization and review its privacy notice first. If it requests a treatment choice, leave the clinical question for a qualified professional.

Our bottom line: GLP1Match.com describes a provider-discovery service with limits on the accuracy of its listings and a disclosure of commercial influences. You can use that information to organize questions, but a directory result is not medical clearance or a confirmed total price. The next useful step is checking the provider’s own current details, not treating the match as a prescription. [S2] [S3]

Sources and scope of this check

Source checks were completed October 9, 2026. GLP1Match.com’s legal pages display a January 1, 2025 update date. We report the pages as found, rather than treating an old displayed date as proof of a recent policy revision. Provider pages and policies can change after a capture. The research supports the narrowly described claims above, not provider outcomes or any compounded formulation. [S2] [S3] [S4]

This guide is a document-based check. It does not include test purchases, contact with providers, insurance determinations, live-form submissions, a security audit or verification of a particular clinician’s license. It makes no individualized eligibility decision. Use the dated documents to decide what to ask next, and seek a clinician’s advice for medical decisions.

Update policy

GLP Clinic Scout editorial update policy, recorded October 9, 2026: the October 9, 2026 source check is this guide’s baseline. We will recheck the relevant sources when directory verification criteria, terms, affiliate disclosures, privacy practices, billing exclusions or renewal terms change, or when the cited FDA-approved Zepbound label is revised. Any resulting correction will identify its new check date; this policy does not imply that a later recheck has already occurred.

Frequently asked questions

Is GLP-1 Match a clinic?

GLP1Match.com’s terms say it is an online aggregator, not a healthcare provider, and that it does not provide medical services, diagnosis or treatment. If you proceed to a third-party provider, that provider’s terms and privacy practices apply separately. A directory search should not be confused with a clinical visit. [S2]

Are GLP1Match.com and MatchGLP1.com the same website?

No: they are different domain names. The pages we checked show provider-discovery filters at GLP1Match.com and a quiz, comparison pages and rankings at MatchGLP1.com. We did not establish their ownership relationship or audit either matching method. Check the spelling of the address when looking for a particular site. [S1] [S5]

Does GLP-1 Match guarantee accurate prices or insurance coverage?

Its terms say it does not warrant that information such as pricing, availability or insurance coverage is complete, accurate, reliable or error-free. Ask the provider and your plan for the details relevant to your situation. Treat a reported directory price as a starting point for questions, not a confirmed bill. [S2]

Can affiliate relationships affect provider presentation?

GLP1Match.com’s disclosure says they may influence which providers or products appear and where or how they are presented. It also describes sponsorships and paid insertions. We have not audited a particular listing’s financial relationship, so we do not infer that any named result is paid or unpaid. [S3]

Is a membership price the full medication cost?

Not necessarily. The checked GoodRx care page explicitly excludes medication cost, and the checked Weight Watchers MED+ offer does too. These examples do not establish every provider’s billing structure. Request the exact product price and any separate service charges for the same period before comparing totals. [S6] [S7]

Does a trial comparison prove which medication is right for me?

No. The SURMOUNT-5 protocol pages checked here describe design and an endpoint, not outcomes or individualized prescribing. The other studies cited here are observational and address group-level care patterns or comparisons. None validates the directory’s matching process or determines your personal treatment choice; discuss that with a qualified clinician. [S9] [S10] [S11] [S12]

What to verify

Confirm

Uses current primary evidence.
Separates verified facts from unknowns.
Maps decision-bearing claims to captured source text.

Do not assume

Terms, prices, labels, and coverage can change.
Individual outcomes and eligibility cannot be inferred from general evidence.
The page cannot replace clinician, plan, or pharmacy verification.

Verified claims

Each statement below is bound to its numbered source.

Open the claim-to-source map (37 claims)

Searching for **glp 1 match** may lead you to GLP1Match.com, a website for comparing telehealth providers. Its terms describe an online aggregator, not a healthcare provider. This guide explains that distinction, separates the similarly named MatchGLP1.com, and gives you questions to take to a provider before paying for care.²³⁶
**Quick answer:** GLP-1 Match at GLP1Match.com helps people discover telehealth providers; it is not a clinic and does not provide medical treatment. Treat a match as a shortlist, not medical clearance. Check the provider’s own terms, complete costs, medication and clinician review. The site discloses that affiliate relationships may influence provider presentation.³⁴
The spelling matters. The homepage at GLP1Match.com offers state and medication filters and a “Verified Providers Only” control. MatchGLP1.com is a different domain whose homepage offers a quiz, comparison pages and rankings. These observations identify the pages we checked; they do not establish that the businesses are affiliated, that their checks are equivalent or that either selects appropriate treatment.²⁶
| GLP1Match.com | Homepage offers provider discovery; terms say it is an aggregator and not a healthcare provider. |²³
| MatchGLP1.com | Separate domain advertises a matching quiz, provider comparison and rankings. |⁶
| A provider selected through GLP1Match.com | Its own terms and privacy practices apply independently of the directory, according to the directory’s terms. |³
The directory’s terms say it helps users locate telehealth providers who may prescribe and deliver GLP-1 medications. They describe searching and comparing by criteria such as location, specialty and price. They also say the platform does not provide medical services, diagnosis or treatment, and does not recommend or endorse a specific medication or healthcare provider.³
The terms explicitly do not warrant that provider qualifications, pricing, availability or insurance coverage are complete, accurate, reliable or error-free. A useful listing therefore still needs a current check with the provider or plan. This is the site’s stated limitation, not evidence that any particular listing is wrong.³
The GLP1Match.com homepage we checked includes the words “Verified Providers Only.” The captured homepage does not explain the verification criteria next to that control. We did not independently establish what was checked, by whom, when it was checked, or whether that check extends to the particular clinician and pharmacy involved in a future prescription.²
GLP1Match.com’s disclosure says some links may be affiliate links and that it may receive a commission after a purchase or another qualifying action. It also states that affiliate relationships may influence which providers or products appear and where or how they are presented. The page separately describes potential sponsorships, paid insertions and advertisements. Its discount-code terms say using a code may give you a discount while GLP1Match.com may receive compensation, such as a commission or referral fee.⁴¹⁴
The same disclosure says paid advertisements do not imply endorsement or approval, and it tells users to consult a qualified healthcare professional before making medical decisions. We report those statements as the platform’s own disclosures; we have not audited its commercial relationships, payments or ranking algorithm.⁴
Two pages in the exact-query search results illustrate the problem. GoodRx’s online weight-loss care page says “Medication cost not included” and “GoodRx is NOT insurance.” Weight Watchers’ MED+ offer similarly says GLP-1 medication costs are not included; its footnote describes different commitment lengths, continuing membership rates and automatic renewal. These are reported page terms, not quotes for your care or recommendations to use either service.⁷⁸
A product name needs its own evidence. For example, the current U.S. Zepbound prescribing-information highlights identify tirzepatide as a GIP and GLP-1 receptor agonist. They indicate use with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or overweight with at least one weight-related comorbid condition. They also include moderate-to-severe obstructive sleep apnea in adults with obesity. These are Zepbound-specific label statements, not a finding about a directory’s eligibility filters. (original PDF page 1)⁹
The label also carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and whether Zepbound causes these tumors in humans is unknown. It lists contraindications including a personal or family history of medullary thyroid carcinoma or MEN 2, and known serious hypersensitivity to tirzepatide or its excipients. This is a selected safety summary, not a complete screening checklist. (original PDF page 1)⁹
Page 1 additionally warns about severe gastrointestinal reactions, acute kidney injury due to volume depletion, gallbladder disease, pancreatitis and serious hypersensitivity reactions. It includes pregnancy precautions and notes potential effects on absorption of oral medications. A comparison filter cannot evaluate those issues; take the full product information and your medical history to a qualified clinician. (original PDF page 1)⁹
The original studies retained for this guide do not validate either directory’s matching process. One retrospective study used health-system records from Ohio and Florida to examine adults with overweight or obesity, without type 2 diabetes, who started injectable semaglutide or tirzepatide. It followed changes through 12 months by discontinuation status. Its authors reported lower average weight reduction than in the main phase 3 trials, likely related to more discontinuation and lower maintenance dosages. This is observational evidence, not a causal test of provider matching.¹¹
A second retrospective study from the same geographic health-system setting examined people who discontinued those medications after starting them for obesity or type 2 diabetes. During the year after discontinuation, restarting the original medication or receiving alternative treatment was common. Average weight change was relatively small, with considerable individual variability. Because later treatment was common, the findings should not be read as the effect of stopping medication without further care.¹²
That second study matters as contrary evidence to a blanket claim that every person follows the same trajectory after stopping. It does not establish that stopping is risk-free or appropriate for you. The studies address different populations and follow-up questions; their averages do not settle an individual treatment plan. Our editorial takeaway is to ask the clinician how follow-up and continuity would be handled, not to predict your result from an average.¹¹¹²
A third, nationwide multicenter observational study compared short-term adverse events, persistence and effectiveness among people with obesity receiving semaglutide or tirzepatide, with analyses through six months. It reported similar overall short-term tolerability and persistence alongside differences in some events and early weight reduction. Treatment was not randomly assigned, so the comparison is not proof that one drug, provider or directory is the best match for an individual.¹³
We also inspected the SURMOUNT-5 trial protocol. Original PDF page 13 describes the weight-change endpoint at 72 weeks; page 14 describes a randomized, open-label, active-controlled comparison in adults with obesity or overweight without type 2 diabetes. Those pages describe study design, not outcome findings. We do not convert the protocol’s objective to demonstrate superiority into a demonstrated result. (original PDF pages 13–14)¹⁰
| Zepbound U.S. prescribing information | Product-specific approved-use and safety information; not directory approval. |⁹
| Ohio/Florida observational cohorts | Routine-care associations and variation; no randomized test of matching sites. |¹¹¹²
| Short-term multicenter observational comparison | Group-level observations through six months; not individual drug selection. |¹³
| SURMOUNT-5 protocol pages | Planned study design and endpoint; these pages are not an outcomes report. |¹⁰
GLP1Match.com’s privacy policy describes it as an aggregator, not a healthcare provider, and says it does not collect medical or health-related information. It states that it does not act as a HIPAA covered entity or business associate. These are policy statements, not an independent security or legal-compliance audit. Do not assume a directory account has the same protections or purpose as a clinical patient portal.⁵
The policy describes collection of contact information when supplied, and automatic device and usage information including IP addresses, referring URLs, pages viewed and links clicked. It names cookies, pixels, Hotjar and Google Analytics. It also describes sharing with service vendors and says, currently, it does not share personal information such as email with telehealth providers. We have not tested whether its live tracking or data flows match those statements.⁵
The directory’s terms say a selected provider’s privacy practices apply independently. Our recommendation is to read that provider’s notice before entering sensitive information. Ask which organization receives an intake, whether you are in a clinical portal and what happens to data if you decide not to proceed. Do not send medical history to a comparison publisher merely to obtain general reading material.³
Our bottom line: GLP1Match.com describes a provider-discovery service with limits on the accuracy of its listings and a disclosure of commercial influences. You can use that information to organize questions, but a directory result is not medical clearance or a confirmed total price. The next useful step is checking the provider’s own current details, not treating the match as a prescription.³⁴
GLP1Match.com’s terms say it is an online aggregator, not a healthcare provider, and that it does not provide medical services, diagnosis or treatment. If you proceed to a third-party provider, that provider’s terms and privacy practices apply separately. A directory search should not be confused with a clinical visit.³
No: they are different domain names. The pages we checked show provider-discovery filters at GLP1Match.com and a quiz, comparison pages and rankings at MatchGLP1.com. We did not establish their ownership relationship or audit either matching method. Check the spelling of the address when looking for a particular site.²⁶
Its terms say it does not warrant that information such as pricing, availability or insurance coverage is complete, accurate, reliable or error-free. Ask the provider and your plan for the details relevant to your situation. Treat a reported directory price as a starting point for questions, not a confirmed bill.³
GLP1Match.com’s disclosure says they may influence which providers or products appear and where or how they are presented. It also describes sponsorships and paid insertions. We have not audited a particular listing’s financial relationship, so we do not infer that any named result is paid or unpaid.⁴
Not necessarily. The checked GoodRx care page explicitly excludes medication cost, and the checked Weight Watchers MED+ offer does too. These examples do not establish every provider’s billing structure. Request the exact product price and any separate service charges for the same period before comparing totals.⁷⁸
No. The SURMOUNT-5 protocol pages checked here describe design and an endpoint, not outcomes or individualized prescribing. The other studies cited here are observational and address group-level care patterns or comparisons. None validates the directory’s matching process or determines your personal treatment choice; discuss that with a qualified clinician.^10111213
Source checks were completed October 9, 2026. GLP1Match.com’s legal pages display a January 1, 2025 update date. We report the pages as found, rather than treating an old displayed date as proof of a recent policy revision. Provider pages and policies can change after a capture. The research supports the narrowly described claims above, not provider outcomes or any compounded formulation.³⁴⁵
The semaglutide and tirzepatide medications discussed here require a prescription from an appropriately licensed clinician. A directory match is neither a prescription nor clinical approval and cannot authorize access to prescription medication. FDA advises obtaining a prescription from a doctor and flags services that supply these medicines without screening and a prescription by a licensed doctor.¹⁵
GLP Clinic Scout’s affiliate disclosure says we may earn a commission at no extra cost to you if you use a partner link. This guide contains no provider affiliate call to action. The practical standard is the same whichever comparison site you use: identify the source, distinguish commercial presentation from medical evidence, and check the terms before committing. Disclosure helps you interpret content; it is not a substitute for verification.¹⁶

Facts to compare

Open the source-bound fact recap (8 rows)

Source-bound facts from this guide
Question	Published fact	Evidence
Cost	Quick answer: GLP-1 Match at GLP1Match.com helps people discover telehealth providers; it is not a clinic and does not provide medical treatment. Treat a match as a shortlist, not medical clearance. Check the provider’s own terms, complete costs, medication and clinician review. The site discloses that affiliate relationships may influence provider presentation.	Mapped claim
Cost	The directory’s terms say it helps users locate telehealth providers who may prescribe and deliver GLP-1 medications. They describe searching and comparing by criteria such as location, specialty and price. They also say the platform does not provide medical services, diagnosis or treatment, and does not recommend or endorse a specific medication or healthcare provider.	Mapped claim
Eligibility or terms	The terms explicitly do not warrant that provider qualifications, pricing, availability or insurance coverage are complete, accurate, reliable or error-free. A useful listing therefore still needs a current check with the provider or plan. This is the site’s stated limitation, not evidence that any particular listing is wrong.	Mapped claim
Cost	Two pages in the exact-query search results illustrate the problem. GoodRx’s online weight-loss care page says “Medication cost not included” and “GoodRx is NOT insurance.” Weight Watchers’ MED+ offer similarly says GLP-1 medication costs are not included; its footnote describes different commitment lengths, continuing membership rates and automatic renewal. These are reported page terms, not quotes for your care or recommendations to use either service.	Mapped claim
Product status	A product name needs its own evidence. For example, the current U.S. Zepbound prescribing-information highlights identify tirzepatide as a GIP and GLP-1 receptor agonist. They indicate use with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or overweight with at least one weight-related comorbid condition. They also include moderate-to-severe obstructive sleep apnea in adults with obesity. These are Zepbound-specific label statements, not a finding about a directory’s eligibility filters. (original PDF page 1)	Mapped claim
Product status	The label also carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and whether Zepbound causes these tumors in humans is unknown. It lists contraindications including a personal or family history of medullary thyroid carcinoma or MEN 2, and known serious hypersensitivity to tirzepatide or its excipients. This is a selected safety summary, not a complete screening checklist. (original PDF page 1)	Mapped claim
Product status	We also inspected the SURMOUNT-5 trial protocol. Original PDF page 13 describes the weight-change endpoint at 72 weeks; page 14 describes a randomized, open-label, active-controlled comparison in adults with obesity or overweight without type 2 diabetes. Those pages describe study design, not outcome findings. We do not convert the protocol’s objective to demonstrate superiority into a demonstrated result. (original PDF pages 13–14)	Mapped claim
Product status	\| Zepbound U.S. prescribing information \| Product-specific approved-use and safety information; not directory approval. \|	Mapped claim

Quick evidence check

What the sources establish

Uses current primary evidence.
Separates verified facts from unknowns.
Maps decision-bearing claims to captured source text.

What still needs verification

Terms, prices, labels, and coverage can change.
Individual outcomes and eligibility cannot be inferred from general evidence.
The page cannot replace clinician, plan, or pharmacy verification.

Sources and what they support

GLP Clinic ScoutBackground source for the guide boundary.GLP Clinic Scout — published pagecurrent as of 2026-10-09
GLP1Match.comSupports: Searching for **glp 1 match** may lead you to GLP1Match.com, a website for comparing telehealth providers. Its terms describe an online aggregator, not a healthcare provider. This guide explains that distinction, separates the similarly named MatchGLP1.com, and gives you questions to take to a provider before paying for care. · The spelling matters. The homepage at GLP1Match.com offers state and medication filters and a “Verified Providers Only” control. MatchGLP1.com is a different domain whose homepage offers a quiz, comparison pages and rankings. These observations identify the pages we checked; they do not establish that the businesses are affiliated, that their checks are equivalent or that either selects appropriate treatment. · | GLP1Match.com | Homepage offers provider discovery; terms say it is an aggregator and not a healthcare provider. | · The GLP1Match.com homepage we checked includes the words “Verified Providers Only.” The captured homepage does not explain the verification criteria next to that control. We did not independently establish what was checked, by whom, when it was checked, or whether that check extends to the particular clinician and pharmacy involved in a future prescription. · No: they are different domain names. The pages we checked show provider-discovery filters at GLP1Match.com and a quiz, comparison pages and rankings at MatchGLP1.com. We did not establish their ownership relationship or audit either matching method. Check the spelling of the address when looking for a particular site.GLP1Match.com — published pagecurrent as of 2026-10-09
GLP1Match.comSupports: Searching for **glp 1 match** may lead you to GLP1Match.com, a website for comparing telehealth providers. Its terms describe an online aggregator, not a healthcare provider. This guide explains that distinction, separates the similarly named MatchGLP1.com, and gives you questions to take to a provider before paying for care. · **Quick answer:** GLP-1 Match at GLP1Match.com helps people discover telehealth providers; it is not a clinic and does not provide medical treatment. Treat a match as a shortlist, not medical clearance. Check the provider’s own terms, complete costs, medication and clinician review. The site discloses that affiliate relationships may influence provider presentation. · | GLP1Match.com | Homepage offers provider discovery; terms say it is an aggregator and not a healthcare provider. | · | A provider selected through GLP1Match.com | Its own terms and privacy practices apply independently of the directory, according to the directory’s terms. | · The directory’s terms say it helps users locate telehealth providers who may prescribe and deliver GLP-1 medications. They describe searching and comparing by criteria such as location, specialty and price. They also say the platform does not provide medical services, diagnosis or treatment, and does not recommend or endorse a specific medication or healthcare provider. · The terms explicitly do not warrant that provider qualifications, pricing, availability or insurance coverage are complete, accurate, reliable or error-free. A useful listing therefore still needs a current check with the provider or plan. This is the site’s stated limitation, not evidence that any particular listing is wrong. · The directory’s terms say a selected provider’s privacy practices apply independently. Our recommendation is to read that provider’s notice before entering sensitive information. Ask which organization receives an intake, whether you are in a clinical portal and what happens to data if you decide not to proceed. Do not send medical history to a comparison publisher merely to obtain general reading material. · Our bottom line: GLP1Match.com describes a provider-discovery service with limits on the accuracy of its listings and a disclosure of commercial influences. You can use that information to organize questions, but a directory result is not medical clearance or a confirmed total price. The next useful step is checking the provider’s own current details, not treating the match as a prescription. · GLP1Match.com’s terms say it is an online aggregator, not a healthcare provider, and that it does not provide medical services, diagnosis or treatment. If you proceed to a third-party provider, that provider’s terms and privacy practices apply separately. A directory search should not be confused with a clinical visit. · Its terms say it does not warrant that information such as pricing, availability or insurance coverage is complete, accurate, reliable or error-free. Ask the provider and your plan for the details relevant to your situation. Treat a reported directory price as a starting point for questions, not a confirmed bill. · Source checks were completed October 9, 2026. GLP1Match.com’s legal pages display a January 1, 2025 update date. We report the pages as found, rather than treating an old displayed date as proof of a recent policy revision. Provider pages and policies can change after a capture. The research supports the narrowly described claims above, not provider outcomes or any compounded formulation.GLP1Match.com — published terms pagecurrent as of 2026-10-09
GLP1Match.comSupports: **Quick answer:** GLP-1 Match at GLP1Match.com helps people discover telehealth providers; it is not a clinic and does not provide medical treatment. Treat a match as a shortlist, not medical clearance. Check the provider’s own terms, complete costs, medication and clinician review. The site discloses that affiliate relationships may influence provider presentation. · GLP1Match.com’s disclosure says some links may be affiliate links and that it may receive a commission after a purchase or another qualifying action. It also states that affiliate relationships may influence which providers or products appear and where or how they are presented. The page separately describes potential sponsorships, paid insertions and advertisements. Its discount-code terms say using a code may give you a discount while GLP1Match.com may receive compensation, such as a commission or referral fee. · The same disclosure says paid advertisements do not imply endorsement or approval, and it tells users to consult a qualified healthcare professional before making medical decisions. We report those statements as the platform’s own disclosures; we have not audited its commercial relationships, payments or ranking algorithm. · Our bottom line: GLP1Match.com describes a provider-discovery service with limits on the accuracy of its listings and a disclosure of commercial influences. You can use that information to organize questions, but a directory result is not medical clearance or a confirmed total price. The next useful step is checking the provider’s own current details, not treating the match as a prescription. · GLP1Match.com’s disclosure says they may influence which providers or products appear and where or how they are presented. It also describes sponsorships and paid insertions. We have not audited a particular listing’s financial relationship, so we do not infer that any named result is paid or unpaid. · Source checks were completed October 9, 2026. GLP1Match.com’s legal pages display a January 1, 2025 update date. We report the pages as found, rather than treating an old displayed date as proof of a recent policy revision. Provider pages and policies can change after a capture. The research supports the narrowly described claims above, not provider outcomes or any compounded formulation.GLP1Match.com — published pagecurrent as of 2026-10-09
GLP1Match.comSupports: GLP1Match.com’s privacy policy describes it as an aggregator, not a healthcare provider, and says it does not collect medical or health-related information. It states that it does not act as a HIPAA covered entity or business associate. These are policy statements, not an independent security or legal-compliance audit. Do not assume a directory account has the same protections or purpose as a clinical patient portal. · The policy describes collection of contact information when supplied, and automatic device and usage information including IP addresses, referring URLs, pages viewed and links clicked. It names cookies, pixels, Hotjar and Google Analytics. It also describes sharing with service vendors and says, currently, it does not share personal information such as email with telehealth providers. We have not tested whether its live tracking or data flows match those statements. · Source checks were completed October 9, 2026. GLP1Match.com’s legal pages display a January 1, 2025 update date. We report the pages as found, rather than treating an old displayed date as proof of a recent policy revision. Provider pages and policies can change after a capture. The research supports the narrowly described claims above, not provider outcomes or any compounded formulation.GLP1Match.com — published pagecurrent as of 2026-10-09
MatchGLP1.comSupports: Searching for **glp 1 match** may lead you to GLP1Match.com, a website for comparing telehealth providers. Its terms describe an online aggregator, not a healthcare provider. This guide explains that distinction, separates the similarly named MatchGLP1.com, and gives you questions to take to a provider before paying for care. · The spelling matters. The homepage at GLP1Match.com offers state and medication filters and a “Verified Providers Only” control. MatchGLP1.com is a different domain whose homepage offers a quiz, comparison pages and rankings. These observations identify the pages we checked; they do not establish that the businesses are affiliated, that their checks are equivalent or that either selects appropriate treatment. · | MatchGLP1.com | Separate domain advertises a matching quiz, provider comparison and rankings. | · No: they are different domain names. The pages we checked show provider-discovery filters at GLP1Match.com and a quiz, comparison pages and rankings at MatchGLP1.com. We did not establish their ownership relationship or audit either matching method. Check the spelling of the address when looking for a particular site.MatchGLP1.com — published pagecurrent as of 2026-10-09
GoodRxSupports: Two pages in the exact-query search results illustrate the problem. GoodRx’s online weight-loss care page says “Medication cost not included” and “GoodRx is NOT insurance.” Weight Watchers’ MED+ offer similarly says GLP-1 medication costs are not included; its footnote describes different commitment lengths, continuing membership rates and automatic renewal. These are reported page terms, not quotes for your care or recommendations to use either service. · Not necessarily. The checked GoodRx care page explicitly excludes medication cost, and the checked Weight Watchers MED+ offer does too. These examples do not establish every provider’s billing structure. Request the exact product price and any separate service charges for the same period before comparing totals.GoodRx — published pagecurrent as of 2026-10-09
Weight WatchersSupports: Two pages in the exact-query search results illustrate the problem. GoodRx’s online weight-loss care page says “Medication cost not included” and “GoodRx is NOT insurance.” Weight Watchers’ MED+ offer similarly says GLP-1 medication costs are not included; its footnote describes different commitment lengths, continuing membership rates and automatic renewal. These are reported page terms, not quotes for your care or recommendations to use either service. · Not necessarily. The checked GoodRx care page explicitly excludes medication cost, and the checked Weight Watchers MED+ offer does too. These examples do not establish every provider’s billing structure. Request the exact product price and any separate service charges for the same period before comparing totals.Weight Watchers — published pagecurrent as of 2026-10-09
Eli Lilly, U.S. Zepbound Prescribing InformationSupports: A product name needs its own evidence. For example, the current U.S. Zepbound prescribing-information highlights identify tirzepatide as a GIP and GLP-1 receptor agonist. They indicate use with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or overweight with at least one weight-related comorbid condition. They also include moderate-to-severe obstructive sleep apnea in adults with obesity. These are Zepbound-specific label statements, not a finding about a directory’s eligibility filters. (original PDF page 1) · The label also carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and whether Zepbound causes these tumors in humans is unknown. It lists contraindications including a personal or family history of medullary thyroid carcinoma or MEN 2, and known serious hypersensitivity to tirzepatide or its excipients. This is a selected safety summary, not a complete screening checklist. (original PDF page 1) · Page 1 additionally warns about severe gastrointestinal reactions, acute kidney injury due to volume depletion, gallbladder disease, pancreatitis and serious hypersensitivity reactions. It includes pregnancy precautions and notes potential effects on absorption of oral medications. A comparison filter cannot evaluate those issues; take the full product information and your medical history to a qualified clinician. (original PDF page 1) · | Zepbound U.S. prescribing information | Product-specific approved-use and safety information; not directory approval. |Eli Lilly, U.S. Zepbound Prescribing Information — PDF documentcurrent as of 2026-10-09
ClinicalTrials.gov, SURMOUNT-5 NCT05822830 protocolSupports: We also inspected the SURMOUNT-5 trial protocol. Original PDF page 13 describes the weight-change endpoint at 72 weeks; page 14 describes a randomized, open-label, active-controlled comparison in adults with obesity or overweight without type 2 diabetes. Those pages describe study design, not outcome findings. We do not convert the protocol’s objective to demonstrate superiority into a demonstrated result. (original PDF pages 13–14) · | SURMOUNT-5 protocol pages | Planned study design and endpoint; these pages are not an outcomes report. | · No. The SURMOUNT-5 protocol pages checked here describe design and an endpoint, not outcomes or individualized prescribing. The other studies cited here are observational and address group-level care patterns or comparisons. None validates the directory’s matching process or determines your personal treatment choice; discuss that with a qualified clinician.ClinicalTrials.gov, SURMOUNT-5 NCT05822830 protocol — PDF documentcurrent as of 2026-10-09
PubMed/NLM, Gasoyan et al., ObesitySupports: The original studies retained for this guide do not validate either directory’s matching process. One retrospective study used health-system records from Ohio and Florida to examine adults with overweight or obesity, without type 2 diabetes, who started injectable semaglutide or tirzepatide. It followed changes through 12 months by discontinuation status. Its authors reported lower average weight reduction than in the main phase 3 trials, likely related to more discontinuation and lower maintenance dosages. This is observational evidence, not a causal test of provider matching. · That second study matters as contrary evidence to a blanket claim that every person follows the same trajectory after stopping. It does not establish that stopping is risk-free or appropriate for you. The studies address different populations and follow-up questions; their averages do not settle an individual treatment plan. Our editorial takeaway is to ask the clinician how follow-up and continuity would be handled, not to predict your result from an average. · | Ohio/Florida observational cohorts | Routine-care associations and variation; no randomized test of matching sites. | · No. The SURMOUNT-5 protocol pages checked here describe design and an endpoint, not outcomes or individualized prescribing. The other studies cited here are observational and address group-level care patterns or comparisons. None validates the directory’s matching process or determines your personal treatment choice; discuss that with a qualified clinician.PubMed/NLM, Gasoyan et al., Obesity — published pagecurrent as of 2026-10-09
PubMed/NLM, Gasoyan et al., Diabetes Obesity and MetabolismSupports: A second retrospective study from the same geographic health-system setting examined people who discontinued those medications after starting them for obesity or type 2 diabetes. During the year after discontinuation, restarting the original medication or receiving alternative treatment was common. Average weight change was relatively small, with considerable individual variability. Because later treatment was common, the findings should not be read as the effect of stopping medication without further care. · That second study matters as contrary evidence to a blanket claim that every person follows the same trajectory after stopping. It does not establish that stopping is risk-free or appropriate for you. The studies address different populations and follow-up questions; their averages do not settle an individual treatment plan. Our editorial takeaway is to ask the clinician how follow-up and continuity would be handled, not to predict your result from an average. · | Ohio/Florida observational cohorts | Routine-care associations and variation; no randomized test of matching sites. | · No. The SURMOUNT-5 protocol pages checked here describe design and an endpoint, not outcomes or individualized prescribing. The other studies cited here are observational and address group-level care patterns or comparisons. None validates the directory’s matching process or determines your personal treatment choice; discuss that with a qualified clinician.PubMed/NLM, Gasoyan et al., Diabetes Obesity and Metabolism — published pagecurrent as of 2026-10-09
PubMed/NLM, Obesity Facts multicenter investigatorsSupports: A third, nationwide multicenter observational study compared short-term adverse events, persistence and effectiveness among people with obesity receiving semaglutide or tirzepatide, with analyses through six months. It reported similar overall short-term tolerability and persistence alongside differences in some events and early weight reduction. Treatment was not randomly assigned, so the comparison is not proof that one drug, provider or directory is the best match for an individual. · | Short-term multicenter observational comparison | Group-level observations through six months; not individual drug selection. | · No. The SURMOUNT-5 protocol pages checked here describe design and an endpoint, not outcomes or individualized prescribing. The other studies cited here are observational and address group-level care patterns or comparisons. None validates the directory’s matching process or determines your personal treatment choice; discuss that with a qualified clinician.PubMed/NLM, Obesity Facts multicenter investigators — published pagecurrent as of 2026-10-09
GLP1Match.comSupports: GLP1Match.com’s disclosure says some links may be affiliate links and that it may receive a commission after a purchase or another qualifying action. It also states that affiliate relationships may influence which providers or products appear and where or how they are presented. The page separately describes potential sponsorships, paid insertions and advertisements. Its discount-code terms say using a code may give you a discount while GLP1Match.com may receive compensation, such as a commission or referral fee.GLP1Match.com — published pagecurrent as of 2026-10-09
U.S. Food and Drug AdministrationSupports: The semaglutide and tirzepatide medications discussed here require a prescription from an appropriately licensed clinician. A directory match is neither a prescription nor clinical approval and cannot authorize access to prescription medication. FDA advises obtaining a prescription from a doctor and flags services that supply these medicines without screening and a prescription by a licensed doctor.U.S. Food and Drug Administration — regulatory documentcurrent as of 2026-10-09
GLP Clinic ScoutSupports: GLP Clinic Scout’s affiliate disclosure says we may earn a commission at no extra cost to you if you use a partner link. This guide contains no provider affiliate call to action. The practical standard is the same whichever comparison site you use: identify the source, distinguish commercial presentation from medical evidence, and check the terms before committing. Disclosure helps you interpret content; it is not a substitute for verification.GLP Clinic Scout — published pagecurrent as of 2026-10-09

Guide disclosures

Questions about this evidence record

What does this guide establish?

What does this guide not determine?

This evidence guide is educational and is not medical advice, diagnosis, individualized eligibility screening, or a treatment recommendation.

Keep reading

Continue the source trail.

Trimi vs yourEra: look past the shared $99 starting price

Both programs displayed compounded semaglutide from $99 per month on the checked date, but that shared number does not make the offers equivalent. Trimi attached its lowest prices to an annual plan and stated free overnight shipping. yourEra listed compounded semaglutide from $99 and compounded tirzepatide from $169, with free shipping and ongoing care-team messaging. Compare the amount due, minimum term, exact product, included care, and current checkout terms before paying.

Gala vs Shed: compare the full terms, not a $20 headline gap

Gala displayed compounded GLP-1/GIP access from $179 per month with a yearly subscription. Shed displayed a GLP-1 injection program from $199 per month, said medication or dose can change the price, and described insurance or cash-pay options. The visible $20 difference is not a complete cost comparison because the term, product, service scope, and payment pathway differ.

Found vs Trimi: two different ways to pay for an online program

Found documents an insurance-help pathway through a free insurance check and work with multiple U.S. carriers, while Trimi documents a self-pay offer whose lowest prices require an annual plan. Found does not guarantee coverage, and its medication and membership or care charges may be separate. Compare Found’s plan-specific responsibility with Trimi’s complete minimum-term obligation before choosing between the payment structures.